US/UK/Canada

Share

Quotes

Our effort to treat multiple myeloma is progressing with our lead candidate drug just entering into a phase 2 study, making it the ideal time for the company to broaden its pipeline to include other cancer indications and fully leverage our expertise in NK cell-therapy
Johan Liwing, CEO of XNK Therapeutics
Pick a time period -
Tags ( Active)

XNK Therapeutics announces study in acute myeloid leukemia (AML) patient samples

December 6th, 2021XNK Therapeutics AB (“XNK”) today announced it will perform a proof of concept study in acute myeloid leukemia (AML) using patient samples from The University of Texas MD Anderson Cancer Center.   The proof of concept study is to determine feasibility to expand and activate NK cells from patients with AML using XNK’s proprietary platform. The goal is to establish patient selection criteria for a clinical trial using XNK’s platform and, ultimately, to develop novel therapeutic approaches for AML patients.   “Autologous treatments have a number of advantages. For

Dr. David Berglund and Dr. Stephen Wooding nominated as new board members at XNK Therapeutics

XNK Therapeutics AB (“XNK”) today announced that Dr. David Berglund and Dr. Stephen Wooding are proposed to be appointed members of the Board of Directors. The decision will be taken at an extra general meeting on October 4, and a notice will be sent out separately.“We are incredibly pleased to be able attract such dedicated life science professionals as David and Stephen to the board. They will definitely add valuable knowledge to XNK.”, said Lena Degling Wikingsson, Chairman of the Board. Dr. Berglund, M.D., Ph.D., M.B.A., is an Associate Professor of Immunology at Uppsala University

XNK Therapeutics appoints Markus Thor as Chief Business Officer

Sept. 3, 2021 XNK Therapeutics AB (“XNK”) today announced the appointment of Markus Thor as Chief Business Officer, effective September 6[th]. He will be member of the company’s management team. Mr. Thor is an experienced business development executive with 25 years’ experience from the life science industry. In previous roles he was responsible for structuring, negotiating and closing a range of global, strategic business agreements, including in- and out-licensing, acquisitions and R&D collaborations. Prior to joining XNK, Mr. Thor worked more than a decade at Biovitrum AB,

XNK Therapeutics Reports First Patient Included in Phase II Study in Multiple Myeloma

July 1, 2021 XNK Therapeutics AB (“XNK”) today announced that the first patient has been included in a Phase II clinical study to treat patients with Multiple myeloma using XNK’s leading autologous natural killer (NK) cell-based candidate drug in combination with Sanofi’s anti-CD38 antibody Sarclisa (Isatuximab).“Having the first patient included in this clinical study is a key step in XNK’s development”, said Johan Liwing, CEO of XNK Therapeutics. “While our leading drug candidate is now entering into Phase II, we are in parallel dedicated to progressing our clinical development plan

XNK Therapeutics appoints Michael Uhlin as Chief Scientific Officer

April 20, 2021 XNK Therapeutics AB (“XNK”) today announced the appointment of Professor Michael Uhlin as Chief Scientific Officer, effective August 1[st]. He will be a member of the company’s management team.Michael Uhlin, PhD, will be responsible for defining, implementing, and developing the company’s scientific strategy. He will lead a team involved in R&D and manufacturing with focus on platform development as well as improving production processes and executing operational research plans. Professor Uhlin received his master’s degree in medical research with a focus on biomedicine

XNK Therapeutics appoints Dr. Johan Aschan as Chief Medical Officer

April 14, 2021 XNK Therapeutics AB (“XNK”) today announced the appointment of Dr. Johan Aschan as Chief Medical Officer, effective July 1[st]. He will be member of the company’s management team.Dr. Aschan received his MD from Karolinska Institutet (KI) in 1985 and his PhD in Clinical Immunology from KI in 1994. He has extensive experience from work within the field of allogenic stem cell transplantation at the Karolinska University Hospital in Huddinge, Sweden, and from various leadership roles within hematology and oncology at Janssen. Most recently, prior to joining XNK, Dr. Aschan

XNK Therapeutics partners with Karolinska Institutet on Phase II study in patients with multiple myeloma with support from Sanofi

XNK Therapeutics AB (“XNK”) today announced that it is entering into a joint Phase II clinical study to treat patients with multiple myeloma using XNK’s leading drug candidate in combination with Sanofi’s anti-CD38 antibody Sarclisa (isatuximab). XNK and Sanofi are both collaborative partners within NextGenNK Competence Center coordinated by Karolinska Institutet.The investigator-initiated Phase II study is made possible by the three parties’ contributions to the trial. XNK will provide its novel autologous NK cell-based product to the study set to take place at the Karolinska University

XNK Therapeutics receives US orphan drug status for NK cell-based immunotherapy in multiple myeloma

November 4, 2020 XNK Therapeutics AB (“XNK”) today announced it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its leading investigational drug candidate in the treatment of multiple myeloma (MM).Receiving ODD status from the FDA for the treatment of multiple myeloma is a critical next step for the development of XNK’s leading investigational drug candidate. XNK has already received ODD status in the EU. “Obtaining an ODD by the FDA is a significant milestone for XNK and our goal of taking the present drug candidate to the next level,”

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe